Amgen to invest $900 million in Ohio biomanufacturing facility

HQ Team

April 26, 2025: Amgen Inc. will expand its Ohio biomanufacturing facility for $900 million, after a recent move to invest $1 billion to build a second manufacturing plant in Holly Springs, North Carolina, US.

Since the passage of the Tax Cuts and Jobs Act of 2017, during the first term of President Donald Trump, Amgen has invested about $5 billion in direct capital expenditure in the US, generating an additional downstream output to the economy of about $12 billion, according to a statement.

Amgen’s investment mirrors other pharmaceutical companies’ announcements in the US as the Trump administration threatens to come down heavily on the industry with sector-specific import tariffs.

“Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988,” said Robert A. Bradway, chairman and chief executive officer at Amgen.

‘Skilled workforce’

“Today’s investment reinforces our ongoing commitment to expanding U.S. manufacturing and ensuring patients around the world have access to our innovative medicines,” he said.

“Ohio offers a supportive business climate, skilled workforce, and strategic location, making it an ideal choice for this next phase of our investment.”

Amgen first entered Ohio in June 2021, when it announced plans to invest in a state-of-the-art biomanufacturing facility in Central Ohio.

That investment marked the company’s expansion into the Columbus Region, which enhanced its US-based manufacturing capabilities and created 400 jobs upon the facility’s opening. The current expansion is slated to create 750 jobs, and Amgen has so far invested $1.4 billion in Central Ohio.

Advancing pipeline

The Ohio expansion “enhances the company’s global biomanufacturing network, leveraging decades of operational expertise and technological advancements,” according to the statement.

“Ohio has built a strong foundation for economic development, which has led companies like Amgen to see Ohio as a premier destination for growth,” said Ohio Governor Mike DeWine.

“We are happy to see Amgen deepen its commitment to our state and look forward to the innovation and economic impact it will drive.”

Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

Other drugmakers who have announced an array of US investments include Novartis, Eli Lilly, Thermo Fisher, Regeneron, and Johnson & Johnson.